



**GIG**  
CYMRU  
**NHS**  
WALES

Bwrdd Iechyd Prifysgol  
Bae Abertawe  
Swansea Bay University  
Health Board

Cadeirydd/Chairman: **Andrew Davies**  
Prif Weithredwr/Chief Executive: **Tracy Myhill**

**gofalu am ein gilydd, cydweithio, gwella bob amser**  
**caring for each other, working together, always improving**

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 16<sup>th</sup> August 2019  
Ein Cyf / Our Ref: 19-E-027

☎ 01639 683312

☎ 01639 648363

🖱 [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk)

Corporate Administration  
Headquarters  
1 Talbot Gateway  
Baglan  
Port Talbot, SA12 7BR

[REDACTED]

[REDACTED]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 22<sup>nd</sup> May 2019. We apologise for the delay in responding. Your request sought information relating to cancer.

Please note that the information is for the period of 1<sup>st</sup> November 2019 to 30<sup>th</sup> April 2019.

- 1. Within your Health Board how many patients are currently (within the past 6 months available) being treated for Non-small cell Lung Cancer (NSCLC) with the following:**

**Paclitaxel - 0**

**Gemcitabine - <5\***

**Osimertinib - <5\***

**Carboplatin and Pemetrexed - 16**

**Cisplatin and Pemetrexed - <5\***

**Pembrolizumab monotherapy/Pembrolizumab in combination – 28**

**Atezolizumab -12**

**Nivolumab - <5\***

**Other active systemic anti-cancer therapy - 70**

- 2a Does your Health Board participate in any ongoing clinical trails for the treatment of Metastatic Non Small Cell Lung cancer patients?**

No



**Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR**

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe  
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

2b **If so how many patients are currently taking part in clinical trials/what is the name(s) of the trials ?**

Not relevant as per question 2a.

3 **Within your Health Board how many patients are currently (within the past 6 months available) being treated for Colorectal Cancer (CRC) with the following:**

**Cetuximab not in combination with FOLFIRIE or FOLOX - <5\***

**Cetuximab in combination with FOLFIRI - 6**

**Cetuximab in combination with FOLFOX - <5\***

**Panitumumab not in combination with FOLFIRI or FOLFOX - <5\***

**Panitumumab in combination with FOLFIRI - 0**

**Panitumumab in combination with FOLFOX - <5\***

**Nivolumab - 0**

**Aflibercept - 0**

**Bevacizumab - <5\***

**Ramucirumab - 0**

**Regorafenib - <5\***

**Sorafenib - 0**

**Other active systemic anti-cancer therapy (eg 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU) - 166**

3a **Does your Health Board participate in any ongoing clinical trials for the treatment of Colorectal cancer patients ?**

Yes

3b **If so how many patients are currently taking part in clinical trials/what is the name(s) of the trials?**

Add Aspirin - 11 patients

Raman - 22 patients

Plato - <5\*

4 **Within your Health Board how many patients are currently (within the past 6 months available) being treated for Head and Neck Cancer (Squamous Cell Carcinoma)?**

Information relating to how many patients are currently being treated for Head and Neck Cancer is not held centrally. To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.



**4a If your Health Board is able to split these patients, how many are locally advanced and how many are recurrent and or metastatic Head and Neck Cancer patients ?**

Not relevant. The Health Board are unable to split these patients.

**4b Of the Head and Neck cancer patients please split by their current drug treatment (if you are unable to split by locally advanced and recurrent please state the total):**

**Carboplatin (only or in combination with 5-FU) - <5\***

**Cisplatin (only or in combination with 5-FU) - 0**

**Cetuximab with / without chemotherapy - 0**

**Cetuximab with radiotherapy - <5\***

**Pembrolizumab monotherapy - 0**

**Pembrolizumab with chemotherapy - 0**

**Nivolumab - <5\***

**Docetaxel (only or in combination with 5-FU) - 0**

**Fluorouracil (5-FU) - 0**

**Radiotherapy only - Unknown – not able to report from ChemoCare**

**Other - 49**

**4c Does your Health Board participate in any ongoing clinical trials for the treatment of Head and Neck cancer patients?**

Yes

**4d If so how many patients are currently taking part in clinical trials/ what is the name(s) of the trials ?**

**Pathos – 6 patients**

**Compare – 8 patients**

**5. Within your Health Board how many patients are currently (within the past 6 months available) being treated for Urothelial Carcinoma UCC) with the following:**

**Cisplatin single agent - 0**

**Cisplatin in combination with another agent -7**

**Carboplatin single agent - 0**

**Carboplatin in combination with another agent - 7**

**Nivolumab - 0**

**Pembrolizumab < 5\***

**Atezolizumab 5**

**Other active systemic anti-cancer therapy - <5\***

**5a Does your Health Board participate in any ongoing clinical trials for the treatment of Metastatic Urothelial Carcinoma patients?**

No.



**5b If so how many patients are currently taking part in clinical trials/  
what is the name(s) of the trials?**

Not Relevant as per question 5a.

\* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2<sup>nd</sup> Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



Pam Wenger  
**Director of Corporate Governance**

